Moreover, sorafenib, a molecular targeted drug for the treatment of advanced hepatocellular carcinoma in clinic, has also been demonstrated to alleviate hepatic fibrosis induced by CCl4 by triggering ferroptosis of HSCs via the Hypoxia-inducible factor 1 alpha (HIF-1α)/SLC7A11 pathway [90]. Here, HIF1A is linked to Hepatic fibrosis.